Biológiai terápia idiopathiás inflammatorikus myopathiákban

Levente Bodoki, Melinda Nagy-Vincze, Zoltán Griger, Andrea Péter, C. András, K. Dankó

Research output: Article

Abstract

Idiopathic inflammatory myopathies are systemic, immune-mediated diseases characterized by proximal, symmetrical, progressive muscle weakness. The aim of this work is to give an overview of the biological therapy used in the treatment of idiopathic inflammatory myopathies. The authors also focus on novel results in the therapy directed against the B-and T-cells. They emphasize the importance of new trials in these diseases which may lead to the introduction of novel therapeutic options in these disorders. Orv. Hetil., 2014, 155(1), 3-10.

Original languageHungarian
Pages (from-to)3-10
Number of pages8
JournalOrvosi Hetilap
Volume155
Issue number1
DOIs
Publication statusPublished - jan. 1 2014

Fingerprint

Biological Therapy
Myositis
Immune System Diseases
Muscle Weakness
Therapeutics
T-Lymphocytes

Keywords

  • anti-TNF-alfa therapy
  • biological therapy
  • idiopathic inflammatory myopathies
  • rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biológiai terápia idiopathiás inflammatorikus myopathiákban. / Bodoki, Levente; Nagy-Vincze, Melinda; Griger, Zoltán; Péter, Andrea; András, C.; Dankó, K.

In: Orvosi Hetilap, Vol. 155, No. 1, 01.01.2014, p. 3-10.

Research output: Article

Bodoki, Levente ; Nagy-Vincze, Melinda ; Griger, Zoltán ; Péter, Andrea ; András, C. ; Dankó, K. / Biológiai terápia idiopathiás inflammatorikus myopathiákban. In: Orvosi Hetilap. 2014 ; Vol. 155, No. 1. pp. 3-10.
@article{989729b73226435680e350e56072dd5e,
title = "Biol{\'o}giai ter{\'a}pia idiopathi{\'a}s inflammatorikus myopathi{\'a}kban",
abstract = "Idiopathic inflammatory myopathies are systemic, immune-mediated diseases characterized by proximal, symmetrical, progressive muscle weakness. The aim of this work is to give an overview of the biological therapy used in the treatment of idiopathic inflammatory myopathies. The authors also focus on novel results in the therapy directed against the B-and T-cells. They emphasize the importance of new trials in these diseases which may lead to the introduction of novel therapeutic options in these disorders. Orv. Hetil., 2014, 155(1), 3-10.",
keywords = "anti-TNF-alfa therapy, biological therapy, idiopathic inflammatory myopathies, rituximab",
author = "Levente Bodoki and Melinda Nagy-Vincze and Zolt{\'a}n Griger and Andrea P{\'e}ter and C. Andr{\'a}s and K. Dank{\'o}",
year = "2014",
month = "1",
day = "1",
doi = "10.1556/OH.2014.29787",
language = "Hungarian",
volume = "155",
pages = "3--10",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Biológiai terápia idiopathiás inflammatorikus myopathiákban

AU - Bodoki, Levente

AU - Nagy-Vincze, Melinda

AU - Griger, Zoltán

AU - Péter, Andrea

AU - András, C.

AU - Dankó, K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Idiopathic inflammatory myopathies are systemic, immune-mediated diseases characterized by proximal, symmetrical, progressive muscle weakness. The aim of this work is to give an overview of the biological therapy used in the treatment of idiopathic inflammatory myopathies. The authors also focus on novel results in the therapy directed against the B-and T-cells. They emphasize the importance of new trials in these diseases which may lead to the introduction of novel therapeutic options in these disorders. Orv. Hetil., 2014, 155(1), 3-10.

AB - Idiopathic inflammatory myopathies are systemic, immune-mediated diseases characterized by proximal, symmetrical, progressive muscle weakness. The aim of this work is to give an overview of the biological therapy used in the treatment of idiopathic inflammatory myopathies. The authors also focus on novel results in the therapy directed against the B-and T-cells. They emphasize the importance of new trials in these diseases which may lead to the introduction of novel therapeutic options in these disorders. Orv. Hetil., 2014, 155(1), 3-10.

KW - anti-TNF-alfa therapy

KW - biological therapy

KW - idiopathic inflammatory myopathies

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84891597746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891597746&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29787

DO - 10.1556/OH.2014.29787

M3 - Article

VL - 155

SP - 3

EP - 10

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 1

ER -